Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus Luisa Lunardon, MD, Aimee S. Payne, MD, PhD Journal of Allergy and Clinical Immunology Volume 130, Issue 3, Pages 800-803 (September 2012) DOI: 10.1016/j.jaci.2012.03.022 Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 HACA-positive pemphigus vulgaris (PV) serum blocks the binding of RTX to B cells. Flow cytometry analysis of PBMCs incubated with biotinylated human IgG1 isotype control (B), biotinylated rituximab (biotin-RTX) (C), biotin-RTX + rat anti-RTX (D), biotin-RTX + HACA-negative PV serum prior to RTX therapy (E), and biotin-RTX + HACA-positive PV serum after RTX therapy (F). Samples were unstained (A) or stained with FITC-streptavidin and Alexa Fluor 647 antihuman CD19. AF, Alexa Fluor; FITC, fluorescein isothiocyanate. Journal of Allergy and Clinical Immunology 2012 130, 800-803DOI: (10.1016/j.jaci.2012.03.022) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions